1-7 of 7
Won-Seog Kim
Close
Sort by
Journal Articles

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie Vose, Monica Elena Cabrera, Ranjana H. Advani, Stefano A. Pileri, Martina Manni, Steven M. Horwitz, Francine M. Foss, Felicitas Hitz, John Radford, Ivan Dlouhy, Carlos Chiattone, Won Seog Kim, Tetiana Skrypets, Arnon Nagler, Judith Trotman, Stefano Luminari, Massimo Federico
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5047–5054.
https://doi.org/10.1182/bloodadvances.2023010037
Published: 2023
Includes: Supplemental data
Journal Articles

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study

Clinical Trials & Observations
Won-Seog Kim, Noriko Fukuhara, Dok-Hyun Yoon, Kazuhito Yamamoto, Toshiki Uchida, Eiju Negoro, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Kensei Tobinai
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4903–4912.
https://doi.org/10.1182/bloodadvances.2022008615
Published: 2023
Journal Articles

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain

Junhun Cho, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim
Journal: Blood Advances
Blood Adv (2022) 6 (24): 6120–6130.
https://doi.org/10.1182/bloodadvances.2021006305
Published: 2022
Journal Articles

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Clinical Trials & Observations
Christian Buske, Wojciech Jurczak, Juan-Manuel Sancho, Edvard Zhavrid, Jin Seok Kim, José-Ángel Hernández-Rivas, Aliaksandr Prokharau, Mariana Vasilica, Rajnish Nagarkar, Larry Kwak, Won-Seog Kim, SangJoon Lee, SungHyun Kim, KeumYoung Ahn, Michinori Ogura
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3354–3361.
https://doi.org/10.1182/bloodadvances.2021004484
Published: 2021
Includes: Supplemental data
Journal Articles

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Clinical Trials & Observations
Constantine S. Tam, Stephen Opat, David Simpson, Gavin Cull, Javier Munoz, Tycel J. Phillips, Won Seog Kim, Simon Rule, Siminder Kaur Atwal, Rachel Wei, William Novotny, Jane Huang, Michael Wang, Judith Trotman
Journal: Blood Advances
Blood Adv (2021) 5 (12): 2577–2585.
https://doi.org/10.1182/bloodadvances.2020004074
Published: 2021
Includes: Supplemental data
Journal Articles

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score

Clinical Trials & Observations
Ho-Young Yhim, Yael Eshet, Ur Metser, Chae-Hong Lim, Katherine Lajkosz, Keren Isaev, Matthew Cooper, Anca Prica, Vishal Kukreti, Sita Bhella, Noémie Lang, Kyung-Han Lee, Wei Xu, David Hodgson, Richard Tsang, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim, Michael Crump, John Kuruvilla, Robert Kridel
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5762–5771.
https://doi.org/10.1182/bloodadvances.2020002814
Published: 2020
Includes: Supplemental data
Journal Articles

Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk

Mariko Witalis, Jinsam Chang, Ming-Chao Zhong, Yasser Bouklouch, Vincent Panneton, Joanna Li, Thorsten Buch, Seok Jin Kim, Won Seog Kim, Young Hyeh Ko, André Veillette, Woong-Kyung Suh
Journal: Blood Advances
Blood Adv (2020) 4 (5): 868–879.
https://doi.org/10.1182/bloodadvances.2019001114
Published: 2020
Includes: Supplemental data